Jiahao Tao

Jiahao Tao

Auto-generated profile, based on publicly available information

Jiahao Tao

Cancer Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine 510405, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Journal of International Medical Research
Verified
Journal Article
Open access
JTJiahao Tao
Jiahao Tao
CZChuangjie Zheng
Chuangjie Zheng
CZCuifen Zhang
Cuifen Zhang
LZLing Zhou
Ling Zhou
ZLZeyu Liu
Zeyu Liu
LZLinzhu Zhai
Linzhu Zhai
Objective: To conduct a network meta-analysis of randomised controlled trials to determine the optimal clinical choice of first-line therapy for patients with ALK receptor tyrosine kinase ( ALK) gene rearrangement non-small cell lung cancer (NSCLC). Methods: Clinical trials in patients with histologically confirmed ALK gene rearrangement NSCLC, that included ALK inhibitors as first-line therapy, were identified using database searches. A Bayesian network meta-analysis was conducted to calculate the efficacy and safety of the included first-line treatments. Results: Nine trials with 2,407 patients were included for analyses. Lorlatinib was better than brigatinib for progression-free survival (PFS) (hazard ratio 0.79, 95% confidence interval 0.63, 0.98). In subgroup analyses, lorlatinib exhibited the highest probability of best PFS ranking in patients with or without baseline brain metastases (38% and 80%, respectively); brigatinib had the highest probability of best PFS ranking among Asian patients (47%). Alectinib offered the highest survival advantage (57% probability), while lorlatinib was likely to be the best treatment for an objective response (41% probability). Alectinib displayed the highest probability of being ranked lowest for grade ≥3 adverse events (86%). Conclusions: Lorlatinib was associated with the best PFS overall, and was suitable for patients with or without brain metastases. Brigatinib was associated with the best PFS in Asian patients.

1 January 2025 in Analytical Cellular Pathology
Verified
Journal Article
Open access
CZChuangjie Zheng
Chuangjie Zheng
YRYingfang Ren
Yingfang Ren
KWKe Wang
Ke Wang
XCXinrong Chen
Xinrong Chen
JTJiahao Tao
Jiahao Tao
LZLinzhu Zhai
Linzhu Zhai
Background: Non–small‐cell lung cancer remains the leading cause of cancer‐related deaths globally, and epidermal growth factor receptor mutations have been identified as crucial drivers of the disease. Encouragingly, epidermal growth factor receptor tyrosine kinase inhibitors have demonstrated promising clinical outcomes. Nonetheless, the emergence of resistance to third‐generation EGFR‐TKIs like osimertinib and almonertinib is an inevitable challenge. Methods: In this study, we generated almonertinib‐resistant cell lines from H‐1975 and HCC827 lung cancer cell lines. We utilized various assays, including cell proliferation assays, hematoxylin and eosin staining, and cell cycle assays, to investigate the characteristics of drug‐resistant cells. Additionally, we performed RNA transcriptome sequencing to identify differentially expressed genes (DEGs) in almonertinib‐resistant cells. To further expand our analysis, we obtained sequencing data of osimertinib‐resistant cells from the Gene Expression Omnibus (GEO) dataset and identified DEGs in these cells. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to assess the biological functions and signaling mechanisms associated with DEGs. Furthermore, the survival prognosis and immune cell infiltration of common differentially expressed genes (co‐DEGs) in osimertinib—and almonertinib‐resistant cells were analyzed, and the expression of a co‐DEG ( IGFBP7 ) was verified through quantitative reverse transcriptase polymerase chain reaction (qPCR) and western blotting (WB) assays. Gene knockdown plasmids were constructed for cell transfection, and the invasive ability of resistant cells was assessed using a Transwell assay following the knockdown of IGFBP7 . Results: Experimental cell counting kit–8 cytotoxicity studies revealed intriguing findings regarding drug resistance in lung cancer cells. Specifically, the IC 50 values and resistance factors of H‐1975 and HCC827 cells were found to be 1.9 nM and 833.58 and 2.2 nM and 631.95, respectively. In addition to these quantitative results, comparative observations of the cell morphology and cell cycle revealed significant alterations in drug‐resistant cells. Transcriptome sequencing analysis identified 220 DEGs between H‐1975 and H‐1975/AR and 736 DEGs between HCC827 and HCC827/AR. Interestingly, screening of overlapping DEGs with osimertinib‐resistant cells in the GEO database identified some common genes, such as IGFBP7 and RFTN1 , which were found to be associated with the improved prognosis of non–small–cell lung cancer by survival analysis. Furthermore, GO analysis and KEGG pathway enrichment analysis revealed different pathway changes in different drug‐resistant cells. Survival analysis indicated that a higher expression of co‐DEGs ( IGFBP7 , RFTN1 ) was associated with a more favorable prognosis. Furthermore, IGFBP7 expression is strongly associated with infiltration levels of CD8+ T cells, Tregs, and macrophage cells in lung adenocarcinoma. Molecular biology experiments confirmed that the mRNA and protein expression level of IGFBP7 were over‐expressed in almonertinib‐resistance cells. H‐1975/AR cells were transfected with si‐ IGFBP7 , and the results of transfection were verified at the mRNA and protein levels. After knocking down gene expression, the IC 50 of the cells was 0.3 ± 0.02 µM, which was significantly lower than that of untransfected cells. Additionally, the invasion of cells in the knockdown group was repressed. Conclusions: These findings indicated that almonertinib and osimertinib exhibited distinct resistance mechanisms in vitro, underscoring the need for tailored treatment approaches.

22 September 2020 in Research Square
Verified
Preprint
Open access
PDF file
YZYuanyuan Zhao
Yuanyuan Zhao
JTJiahao Tao
Jiahao Tao
ZCZhuangzhong Chen
Zhuangzhong Chen
SLSuihui Li
Suihui Li
ZLZeyu Liu
Zeyu Liu
LZLinzhu Zhai
Linzhu Zhai
Background The anti-tumor properties of curcumin have been elucidated in many cancer types. However, a systematic functional and biological analysis related to its target proteins has yet to be documented fully. The aim of this study was to explore the underlying mechanisms of curcumin and broaden the perspective of targeted therapies. Methods Direct protein targets (DPTs) of curcumin were searched in the DrugBank database. Using the STRING database, the interaction between curcumin and DPTs and indirect protein targets (IPTs) was documented. The protein–protein interaction (PPI) network of curcumin-mediated proteins was visualized using Cytoscape. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed for all curcumin-mediated proteins. Furthermore, the cancer targets were searched in the Comparative Toxicogenomics Database (CTD). The overlapping targets were studied using Kaplan–Meier analysis to evaluate cancer survival. Further genomic analysis of overlapping genes was conducted using the cBioPortal database. Lastly, CKK-8, qPCR, and WB analysis were used to validate the predicted results on HCC cells. Results A total of 5 DPTs and 199 IPTs were found. These protein targets were found in 121 molecular pathways analyzed via KEGG enrichment. Based on the anti-tumor properties of curcumin, two pathways were selected, including pathways in cancer (36 genes) and hepatocellular carcinoma (HCC) pathway (22 genes). Overlapping with 505 HCC-related gene sets identified in CTD, five genes (TP53、 RB1、 TGFB1、 GSTP1、 and GSTM1) were finally identified. High mRNA levels of TP53, RB1, and GSTM1 indicated a prolonged OS in HCC, while elevated mRNA levels of TGFB1 were correlated with poor prognosis. The viability of HepG2 cells and Hep3B cells can both be significantly reduced by curcumin at concentrations of 20 or 30 µM after 48 or 72 h of culture. At a concentration of 20 µM curcumin, the expression of TGFB1 and GSTP1 in Hep3B cells was reduced significantly in qPCR analysis, and reduced TGFB1 protein expression was also found in Hep3B cells. Conclusions The current results provided evidence that curcumin has the potential to become an alternative chemotherapy or chemoprevention for HCC.